In 2010, an interesting paper published in Nature Medicine [45] studied the role of LOXL2 in rodent pulmonary/liver fibrosis and cancer models and the benefit of inhibition by a monoclonal antibody (AB0023) AB0023 inhibited vessel branching, number, and length in a dose-dependent manner, with complete inhibition at the highest concentration. The gene discussed is LOXL2; the disease is Hepatic fibrosis.